Novel Mesenchymal Stem Cell Delivery System as Targeted Therapy Against Neuroblastoma Using the TH-MYCN Mouse Model

This preclinical study demonstrates that allogeneic mouse mesenchymal stem cells home to neuroblastoma tumors and persist for up to 14 days, functioning as targeted drug delivery vehicles. When engineered to express interferon-beta, these MSCs significantly improved survival in the TH-MYCN mouse model, suggesting a promising therapeutic approach for pediatric neuroblastoma.